Transportation is not a soft, patient-experience issue in clinical trials. It's a protocol execution risk. When participants miss visits because getting to the site is difficult, timelines slip, data gaps grow, and site burden increases, which is why sponsors who evaluate transportation risk early in protocol design are better positioned to protect timelines, retention, and overall study performance.
Key Takeaways
This article covers what the data shows about transportation barriers, how they affect enrollment and retention, and what sponsors can do to reduce risk while maintaining protocol integrity.
Clinical trials frequently struggle with enrollment and retention:
Exact percentages vary by therapeutic area and geography, but the pattern holds: distance, transportation logistics, missed work, caregiver coordination, and physical limitations all contribute meaningfully to missed or rescheduled visits. For sponsors, that translates into missed visit windows, protocol deviations, increased variability in endpoint timing, additional monitoring and rescheduling costs, and a higher risk of incomplete datasets. Patient-centric design isn't primarily about satisfaction. It's about reducing these downstream operational consequences.
Transportation challenges compound in a few predictable scenarios: long study duration, high visit frequency, elderly or mobility-limited populations, rural or geographically dispersed recruitment, and specialized endpoints available only at a limited number of sites. Each of these increases the probability that a participant will miss at least one scheduled visit, and when that visit is tied to a primary or secondary endpoint, the impact is magnified.
Traditional mitigation strategies each carry trade-offs:
The real question for sponsors is how to reduce travel burden without introducing additional operational variability in its place.
Missed visits aren't just schedule disruptions. They affect data quality in measurable ways: missed or out-of-window assessments reduce statistical power, repeated rescheduling increases inter-visit variability, delays in time-sensitive endpoints can alter interpretability, and increased site workload contributes to monitoring findings and documentation risk.
Patient-centric trials that reduce burden tend to see improved adherence to visit schedules and reduced deviation rates, supporting both data quality and retention. This doesn't replace site or PI oversight. It supports their ability to execute the protocol as designed, with the objective of preserving protocol integrity while lowering avoidable friction.
1. Satellite or community sites: Expanding the site footprint closer to participants reduces travel, but at the cost of increased oversight, contracting, and training complexity across each new location.
2. Decentralized and hybrid visits: Remote data capture, telemedicine integration, and remote monitoring reduce travel for some visit types, but not all endpoints are suitable for remote collection.
3. Point-of-need clinical services: Bringing trained clinical teams and calibrated equipment closer to participants, often in community-based settings, can reduce travel distance significantly. In ophthalmic trials specifically, community-based deployment models have shown meaningful reductions in average participant travel miles compared to centralized academic sites, with published sponsor case examples showing reductions exceeding 80% in some programs. 20/20 Onsite's point-of-need ophthalmic clinical trial solutions are built around this exact model.
The strategic benefit isn't convenience alone. It's a better probability of visit completion within protocol windows.
Trials with ophthalmic endpoints carry their own version of this challenge. Visual acuity testing, optical coherence tomography, intraocular pressure measurement, fundus photography, and standardized refraction all require calibrated equipment, trained technicians, and strict protocol adherence. Historically, that limited these assessments to specialized sites, often increasing travel burden for participants enrolled outside major metro areas, which creates a specific risk: missed or delayed endpoint assessments that directly affect primary or key secondary outcomes.
In ophthalmology-inclusive trials, sponsors and CROs should evaluate these factors during study design:
The goal isn't to replace site oversight. It's to extend operational capability in a compliant, protocol-aligned way.
Consider these questions during protocol design and early enrollment:
If the answer to several of these is yes, transportation isn't a theoretical issue in your trial. It's an operational variable that needs a plan.
The most effective patient-centric programs reduce unnecessary travel without compromising endpoint rigor, maintain calibration and standardized data collection, integrate cleanly with sponsor and CRO oversight, lower deviation rates tied to avoidable friction, and protect timelines by improving visit adherence. Done correctly, patient-centric design strengthens both recruitment and retention while preserving data integrity, rather than trading one for the other.
If you're designing or managing a trial where travel burden may affect enrollment, retention, or endpoint timing, it's worth evaluating the operational model early rather than after enrollment stalls. A structured consultation can assess visit schedule risk, endpoint sensitivity to missed windows, geographic dispersion of the target population, feasibility of alternative delivery models, and impact on monitoring and oversight.
The objective is simple: reduce avoidable friction, protect the protocol, and improve the probability of on-time, on-budget completion. Book a consultation to review transportation-related risk factors in your current or upcoming study, and assess whether your trial design supports truly patient-centric execution without compromising scientific rigor.
Why is transportation considered a protocol risk rather than just a patient experience issue? Because missed visits caused by transportation difficulty directly produce missed visit windows, protocol deviations, and incomplete datasets. Those are execution problems that affect timelines and data quality, not just participant satisfaction.
What percentage of clinical trials are delayed due to enrollment or dropout issues? More than 80% to 90% of clinical trials experience delays often tied to enrollment challenges or dropout, according to systematic reviews from the National Library of Medicine. Roughly 30% of participants drop out before completion, with higher rates in longer, more complex Phase 3 studies.
How much can point-of-need clinical services reduce participant travel distance? Published sponsor case examples in ophthalmic trials have shown reductions in average participant travel distance exceeding 80% when community-based, point-of-need deployment models replace centralized academic sites.
What questions should sponsors ask to assess transportation risk in a trial? Whether participants are traveling more than 50 miles for key visits, whether visit windows are narrow or tied to critical endpoint timing, whether the population is elderly or mobility-limited, and whether missed visits or site scheduling strain are already trending upward during early enrollment.
Can decentralized or hybrid trial models fully solve transportation barriers for ocular endpoints? Not on their own. Ophthalmic assessments like OCT, IOP measurement, and standardized refraction require calibrated equipment and trained technicians, which most remote or fully virtual models can't replicate. Point-of-need, community-based delivery addresses the travel barrier while keeping the assessment itself in-person and controlled.
How does 20/20 Onsite help sponsors reduce transportation-related trial risk? 20/20 Onsite's point-of-need ophthalmic clinical trial solutions bring trained clinical teams and calibrated equipment closer to participants in community-based settings, reducing travel distance while maintaining the standardized data collection and oversight sponsors need for protocol integrity.
What operational models exist to reduce clinical trial travel burden? The three most common are expanding to satellite or community sites, adopting decentralized or hybrid visit models for suitable endpoints, and deploying point-of-need clinical services that bring calibrated equipment and trained staff directly to participants.